Full Press Release Details
SOUTH SAN FRANCISCO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that on March 2, 2020, the Company granted two new employees options to purchase a total of 70,000 shares of the Company’s common stock at an exercise price per share equal to $3.61, which was the closing trading price on March 16, 2020, the date of the grant.
The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in September 2019 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About CytomX Therapeutics
PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.
Investors and Media:
VP, Investor Relations and Corporate Communications